Innovative antiviral compounds: the first effective method for treatment of enterovirus infections
| Reference number | |
| Coordinator | Curovir AB |
| Funding from Vinnova | SEK 300 000 |
| Project duration | March 2017 - July 2017 |
| Status | Completed |
| Venture | Innovative Startups |
| Call | Innovativa startups fas 1 Våren 2017 |
Important results from the project
The aim of the phase 1 project was to a) develop synthetic methods for the synthesis of substances on a larger scale, b) evaluate substances in different in vitro models and c) investigate different ADME / PK parameters for selecting a smaller number of substances for in vivo studies (the planned phase 2 project). The final goal of the phase 1 and the phase 2 project is to choose a so-called "candidate drug" for preclinical development.
Expected long term effects
We have succeeded in completing the phase 1 project as planned and the results are positive. We have identified about 10 substances that we will take to the phase 2 project (that includes toxicity studies and in-vivo in-vivo studies).
Approach and implementation
The project consisted of three work packages (WP): WP1 Synthesis of new substances WP2 In-vitro studies WP3 ADME/PK studies Design of new substances was based on SAR information from the previous phase of the development. Substances were synthesized and tested in a variety of assays at our lab and in collaboration with a partner. The summary of the results was made and showed that we have about 10 substances that can be used in the next phase.